News

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

Preoperative knee extensor muscle strength training in patients with knee osteoarthritis may have no clinical effect on total knee arthroplasty (TKA), according to a systematic review published online this month in Osteoarthritis and Cartilage.

This approval makes the drug the first of its kind to treat polyarticular juvenile idiopathic arthritis and psoriatic arthritis in a pediatric population.

The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Autologous hematopoietic stem cell transplants (AHSCT) improve the quality of life in patients with systemic sclerosis (SSc), researchers say.

Various drug therapies, including several cytokine blockers, are showing promise in addressing COVID-19 related cytokine storm syndrome, says Dr. Randall Cron of Children’s Hospital of Alabama.

Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus

The approval of tocilizumab for giant cell arteritis as a glucocorticoid-sparing treatment is the most significant development in the management of this condition over the past four years, a review of the literature suggests.

Some drugs used to treat lupus and other connective tissue diseases have been shown to increase cardiovascular risks. Even so, those drugs remain effective in addressing disease symptoms, and a leading rheumatology researcher has suggested that concerns may not be fully warranted.

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

Black patients with knee osteoarthritis have worse outcomes than their white counterparts, shows a new study.

Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.

Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.

Adherence to a Mediterranean diet is associated with improved musculoskeletal health and fewer falls, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting held earlier this month.

Low-dose oral glucocorticoid therapy increases only vertebral fracture risk in rheumatoid arthritis patients, a study shows.

Findings indicate placebo responses are more than a psychological placebo effect.

An expert discusses the difficulties in diagnosing and managing myositis, as well as how the COVID-19 pandemic has affected clinical care.

Low levels of osteocalcin are associated with an increased risk of diabetes in patients treated with glucocorticoids, according to a study presented on Sept. 11 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which wrapped this week as a virtual meeting.

Improving vitamin D status might decrease the risk of developing severe respiratory distress and death in COVID-19 cases, shows an observational study presented September 11 at the American Society for Bone and Mineral Research (ASBMR) which was held virtually this week.

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.

Spending more time in high-intensity physical activity in early life may protect against osteoporosis in later life, and men are more successful at this than women, according to a study recently published in JAMA Network Open.

An expert discusses the state of screening, diagnosing, and treating osteoarthritis and osteoporosis.

Drug therapy appears to be the first-line option for reducing fracture risk in osteoporosis, but it is not always feasible, and increasing calcium, vitamin D and protein intake may be a more practical option.

High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.

Which composite measures detect the highest level of changes in psoriatic disease activity.

Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.